i2 Technologies, Inc.

Ananth   Raman; Jasjit  Singh

Case | HBS Case Collection | December 1998 (Revised February 1999)

i2 Technologies, Inc.

by Ananth Raman and Jasjit Singh

Abstract

Describes the emergence and growth of i2 Technologies and the supply chain planning software industry. In December 1998, i2's market capitalization was in excess of $2 billion; the supply chain planning software industry had annual sales of approximately $1 billion and was expected to grow at 57% annually. By describing i2's products and the process that the company followed to sell and implement its software at companies, the case provides students with the background needed to understand why i2 was successful. This understanding enables students to address issues like what i2 should do in the future, and whether new competition such as SAP poses a substantial threat to i2's future success.

Keywords: Technology; Information Technology; Software; Supply Chain Management; Production; Forecasting and Prediction; Information Technology Industry;

Format: Print

21 pages

Educators Purchase

Citation:

Raman, Ananth, and Jasjit Singh. "i2 Technologies, Inc." Harvard Business School Case 699-042, December 1998. (Revised February 1999.)

Celebrated as one of the world's premiere luxury hotel brands, Oberoi Hotels attracts and serves some of the most quality sensitive guests in the world. The case considers the challenge of how an organization with a standardized service model can repeatedly delight customers whose expectations grow with every interaction. To explore this question, the case details the design elements of Oberoi's complex service operation, including its approaches to employee management and continuous improvement, as well as the dynamics of service competition in a rapidly growing market.

In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his and other rare cancers. Two years later, the company had several drugs in promising stages of development but were at least 3 to 5 years away from commercialization, if they made it through clinical trials successfully. Only about 4% of drugs that enter clinical trials receive U.S. FDA approval. It is October 2018, and Shepherd is running out of money. Hysong needs to raise $5 million to fund operations for 2019 and at least $20 million for the following few years. But the company is too early to attract the type of venture capital he needs. Even if he got financing, Hysong worried that the company’s mission could be compromised by investors more interested in a return on their investment than saving lives, and he worried about the scaling challenges ahead.

Faculty & Research

i2 Technologies, Inc.

Abstract

Citation:

About the Author

More from the Author